LOS ANGELES--(EON: Enhanced Online News)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Orthofix International N.V. (“Orthofix” or the “Company”) (Nasdaq: OFIX) concerning possible violations of federal securities laws.
“FDA is actively moving to ‘down classify’ BGS from Class III to Class II, allowing cheap competition to flood in, stealing revenues and crushing margins.”
If you purchased or otherwise acquired Orthofix shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
SeekingAlpha.com released a report stating how the “FDA is actively moving to ‘down classify’ BGS from Class III to Class II, allowing cheap competition to flood in, stealing revenues and crushing margins.” The report also states that as of October 1, 2016 “the FDA just transferred the BGS down classification process to the specific department responsible for handling the down classification (the department of Orthopedics).” When this information was released to the public, Orthofix stock declined, causing investors severe harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.